SCIRP Mobile Website
Paper Submission

Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

 

Contact Us >>

Article citations

More>>

Burkhardt, J.K., Riina, H., Shin, B.J., Christos, P., Kesavabhotla, K., Hofstetter, C.P., et al. (2012) Intra-Arterial Delivery of Bevacizumab after Blood-Brain Barrier Disruption for the Treatment of Recurrent Glioblastoma: Progression-Free Survival and Overall Survival. World Neurosurgery, 77, 130-134. http://dx.doi.org/10.1016/j.wneu.2011.05.056

has been cited by the following article:

  • TITLE: Recurrent Glioblastoma Multiforme—A Strategy for Long-Term Survival

    AUTHORS: Stanislaw R. Burzynski, Gregory S. Burzynski, Tomasz J. Janicki

    KEYWORDS: Antineoplastons A10 and AS2-1, Recurrent Glioblastoma Multiforme, HDAC Inhibitor, Phase II Clinical Trials, Glioblastoma Survival, Phenylbutyrate, Targeted Therapy

    JOURNAL NAME: Journal of Cancer Therapy, Vol.5 No.10, September 10, 2014

    ABSTRACT: Recurrent GBM (RGBM) has a highly unfavorable prognosis with majority of patients dying within 6 months and no standard treatments available. Antineoplaston (ANP) A10 and AS2-1 injections underwent Phase II trials in RGBM patients, which reported a long-term overall survival (OS) in a small percentage of patients. The additional Phase II studies BT-07, and BT-21 with ANP in GBM also revealed cases of a long-term OS. ANP shares active ingredients with metabolites of sodium phenylbutyrate (PB), which was used in private practice setting in combination of targeted and chemotherapeutic agents for the treatment of RGBM. The treatment contributed to cases of rapid complete response (CR) and significant OS. This paper provides case studies of three patients treated with ANP under Phase II protocols and two patients treated with PB in combination with targeted therapy, who obtained CR and long-term OS. Based on these studies and basic research on the effects of ANP and PB on the genome of GBM and review of results of preclinical and clinical research on targeted agents, the authors suggest a new strategy for successful treatment of RGBM. They propose Phase I/II clinical trials with ANP and PB in combination with targeted agents, bevacizumab (BVZ), pazopanib, dasatinib and everolimus in patients with RGBM after failure of standard surgery, radiation therapy (RT) and chemotherapy including temozolomide (TMZ) to be conducted to evaluate survival, response and toxicity in these patients.